I. The Industry Has More Data Than Vision Biotechnology has become extraordinarily good at seeing the small. It can sequence a tumor, profile a transcriptome, quantify protein expression, monitor oxygen transfer, measure immune activation, model binding affinity, and predict structure at a level of resolution that would have seemed impossible a generation ago. It can […]
Tag: Biotech
The Trust Layer: Why 2026 Rewards Platforms, Not Point Solutions
2026 is the inflection point where biotechnology stops being priced on promise and starts being priced on conversion. This isn’t a change in sentiment. It’s a change in operating constraints. Capital, regulators, and operators now press the same question: can you keep truth intact as a programme moves from concept to scale—through handoffs, pressure, and […]
Why 2026 Is the Year Systems Beat Stories
(A note on: biotech, techbio, food tech, and the new operating physics of “real companies”) Every cycle reaches a point where narrative stops clearing the bar. The change is not theatrical. It shows up as a shift in diligence questions—questions that are operational, specific, and hard to bluff. When the questions change, the valuation framework […]
Biotech in 2026: The Real Bottlenecks in Scale-Up, Manufacturing, Capital, and Regulation
Where Biotech Actually Fails: Scale Is Not an Extension of the Lab Biotech still tells itself that scale is a later problem. In biotech in 2026, that belief is no longer naive — it is actively dangerous. The lab works.The data looks good.The organism behaves.The molecule binds.The titer hits the slide. And somewhere between that […]